JP2022501338A5 - - Google Patents

Info

Publication number
JP2022501338A5
JP2022501338A5 JP2021514381A JP2021514381A JP2022501338A5 JP 2022501338 A5 JP2022501338 A5 JP 2022501338A5 JP 2021514381 A JP2021514381 A JP 2021514381A JP 2021514381 A JP2021514381 A JP 2021514381A JP 2022501338 A5 JP2022501338 A5 JP 2022501338A5
Authority
JP
Japan
Prior art keywords
triazolo
yloxy
pyrimidine
methylphenyl
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021514381A
Other languages
English (en)
Japanese (ja)
Other versions
JP7546550B2 (ja
JP2022501338A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/106233 external-priority patent/WO2020057511A1/en
Publication of JP2022501338A publication Critical patent/JP2022501338A/ja
Publication of JP2022501338A5 publication Critical patent/JP2022501338A5/ja
Priority to JP2024120830A priority Critical patent/JP2024164018A/ja
Application granted granted Critical
Publication of JP7546550B2 publication Critical patent/JP7546550B2/ja
Priority to JP2025150799A priority patent/JP2026009898A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021514381A 2018-09-18 2019-09-17 抗腫瘍剤としてのキナゾリン誘導体 Active JP7546550B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024120830A JP2024164018A (ja) 2018-09-18 2024-07-26 抗腫瘍剤としてのキナゾリン誘導体
JP2025150799A JP2026009898A (ja) 2018-09-18 2025-09-11 抗腫瘍剤としてのキナゾリン誘導体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2018106098 2018-09-18
CNPCT/CN2018/106098 2018-09-18
CNPCT/CN2019/091078 2019-06-13
CN2019091078 2019-06-13
PCT/CN2019/106233 WO2020057511A1 (en) 2018-09-18 2019-09-17 Quinazoline derivatives as antitumor agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024120830A Division JP2024164018A (ja) 2018-09-18 2024-07-26 抗腫瘍剤としてのキナゾリン誘導体

Publications (3)

Publication Number Publication Date
JP2022501338A JP2022501338A (ja) 2022-01-06
JP2022501338A5 true JP2022501338A5 (cg-RX-API-DMAC7.html) 2022-09-28
JP7546550B2 JP7546550B2 (ja) 2024-09-06

Family

ID=69888359

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021514381A Active JP7546550B2 (ja) 2018-09-18 2019-09-17 抗腫瘍剤としてのキナゾリン誘導体
JP2024120830A Withdrawn JP2024164018A (ja) 2018-09-18 2024-07-26 抗腫瘍剤としてのキナゾリン誘導体
JP2025150799A Pending JP2026009898A (ja) 2018-09-18 2025-09-11 抗腫瘍剤としてのキナゾリン誘導体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024120830A Withdrawn JP2024164018A (ja) 2018-09-18 2024-07-26 抗腫瘍剤としてのキナゾリン誘導体
JP2025150799A Pending JP2026009898A (ja) 2018-09-18 2025-09-11 抗腫瘍剤としてのキナゾリン誘導体

Country Status (19)

Country Link
US (2) US11723908B2 (cg-RX-API-DMAC7.html)
EP (3) EP4360713B1 (cg-RX-API-DMAC7.html)
JP (3) JP7546550B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250171398A (cg-RX-API-DMAC7.html)
CN (2) CN112654612A (cg-RX-API-DMAC7.html)
AU (4) AU2019341273B2 (cg-RX-API-DMAC7.html)
CA (1) CA3099776A1 (cg-RX-API-DMAC7.html)
DK (2) DK3853220T3 (cg-RX-API-DMAC7.html)
ES (2) ES2971927T3 (cg-RX-API-DMAC7.html)
FI (2) FI4360713T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20240293T1 (cg-RX-API-DMAC7.html)
HU (2) HUE069764T2 (cg-RX-API-DMAC7.html)
LT (2) LT4360713T (cg-RX-API-DMAC7.html)
PL (2) PL4360713T3 (cg-RX-API-DMAC7.html)
PT (2) PT4360713T (cg-RX-API-DMAC7.html)
RS (2) RS65413B1 (cg-RX-API-DMAC7.html)
SI (2) SI4360713T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202400524T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020057511A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019196622A1 (zh) * 2018-04-09 2019-10-17 威尚(上海)生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
CN110357858B (zh) 2018-04-09 2022-02-18 威尚(上海)生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
HRP20240293T1 (hr) * 2018-09-18 2024-05-24 F. Hoffmann - La Roche Ag Derivati kinazolina kao protutumorska sredstva
CN111377850B (zh) * 2018-12-31 2022-10-18 艾琪康医药科技(上海)有限公司 一种手性n-取代-3,3-二氟-4-羟基哌啶衍生物及其制备方法
CN113527215B (zh) * 2020-04-17 2023-12-05 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、制备方法及其应用
WO2021209039A1 (zh) * 2020-04-17 2021-10-21 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、制备方法及其应用
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Her2突變抑制劑
JP7598180B2 (ja) * 2021-03-19 2024-12-11 北京賽特明強医薬科技有限公司 キナゾリン系化合物、キナゾリン系化合物の組成物及び応用
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CN117940424A (zh) * 2021-06-22 2024-04-26 缆图药品公司 Egfr抑制剂
WO2022271749A1 (en) * 2021-06-22 2022-12-29 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
US20240382483A1 (en) * 2021-06-22 2024-11-21 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
CN117836286A (zh) 2021-06-22 2024-04-05 缆图药品公司 用于治疗癌症的杂环egfr抑制剂
CN115894455B (zh) * 2021-09-30 2024-04-19 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、组合物及其应用
CN115894383B (zh) * 2021-09-30 2025-12-19 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、组合物及其应用
CR20240163A (es) * 2021-10-20 2024-06-12 Hoffmann La Roche Formas cristalinas de derivados de quinazolina, preparación, composición y uso de estas
CN116478129B (zh) * 2022-01-21 2025-01-07 深圳默元生物科技有限公司 喹啉化合物及其用途
CA3245866A1 (en) * 2022-03-14 2023-09-21 Huyabio International, Llc Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof
US20250206760A1 (en) * 2022-03-28 2025-06-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof
CN115650977A (zh) * 2022-10-09 2023-01-31 广东润兴生物科技有限公司 一种妥卡替尼的合成方法
TW202446386A (zh) * 2023-04-14 2024-12-01 大陸商迪哲(江蘇)醫藥股份有限公司 喹唑啉ErbB抑制劑的藥物形式
WO2024249642A1 (en) * 2023-06-02 2024-12-05 Acerand Therapeutics (Hong Kong) Limited Egfr inhibitors
EP4786473A1 (en) * 2023-09-27 2026-08-05 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutically acceptable salt and crystalline form of quinazoline derivative, and use thereof
TW202602446A (zh) 2024-03-19 2026-01-16 瑞士商豪夫邁 羅氏有限公司 Erbb2抑制劑的藥物製劑

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1985003357A1 (en) 1984-01-30 1985-08-01 Icrf Patents Ltd. Improvements relating to growth factors
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US6743782B1 (en) 1987-10-28 2004-06-01 Wellstat Therapeutics Corporation Acyl deoxyribonucleoside derivatives and uses thereof
EP0494135B1 (en) 1989-09-29 1996-04-10 Oncogene Science, Inc. Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
CN1437594A (zh) 2000-06-22 2003-08-20 辉瑞产品公司 用于治疗异常细胞生长的取代的双环衍生物
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
KR20030014425A (ko) 2000-07-07 2003-02-17 앤지오젠 파마슈티칼스 리미티드 혈관 손상제인 콜치놀 유도체
RU2004116911A (ru) * 2001-11-03 2005-11-10 Астразенека Аб (Se) Производные хиназолина в качестве противоопухолевых средств
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2004000529A1 (de) 2002-06-24 2003-12-31 Fagerdala Deutschland Gmbh Verfahren zur herstellung von bauteilen aus hochgradig lignocellulosefaser-gefüllten thermoplasten
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4828421B2 (ja) 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
DE602006021645D1 (de) * 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
KR20090090336A (ko) * 2006-12-12 2009-08-25 다케다 야쿠힌 고교 가부시키가이샤 융합된 헤테로시클릭 화합물
CN115057861A (zh) * 2016-03-01 2022-09-16 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
EP3516071B1 (en) * 2016-09-22 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of lung cancer
CN109422755B (zh) 2017-09-01 2023-07-04 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
CN111630046B (zh) * 2017-12-19 2023-01-10 成都金瑞基业生物科技有限公司 喹唑啉衍生物及其应用
WO2019214651A1 (zh) * 2018-05-08 2019-11-14 南京明德新药研发有限公司 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
TWI811358B (zh) 2018-05-08 2023-08-11 大陸商迪哲(江蘇)醫藥股份有限公司 ErbB受體抑制劑
HRP20240293T1 (hr) * 2018-09-18 2024-05-24 F. Hoffmann - La Roche Ag Derivati kinazolina kao protutumorska sredstva

Similar Documents

Publication Publication Date Title
HRP20240293T1 (hr) Derivati kinazolina kao protutumorska sredstva
US12486290B2 (en) Isoindolinone and indazole compounds for the degradation of EGFR
ES2377849T3 (es) Compuestos amino-heterocíclicos
JP2024510606A5 (cg-RX-API-DMAC7.html)
JP6537527B2 (ja) Jak及びpi3k阻害剤併用によるb細胞悪性腫瘍の処置
JP2025003975A (ja) PI3Kδ関連障害治療のためのピラゾロピリミジン誘導体の使用
JP6585158B2 (ja) ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体
JP2019517596A5 (cg-RX-API-DMAC7.html)
DK2864295T3 (en) Hitherto UNKNOWN 2,3-DIHYDRO-1H-IMIDAZO {1,2-A} PYRIMIDIN-5-ON AND THIS1,2,3,4-TETRAHYDROPYRIMIDO {1,2-A} PYRIMIDIN-6 SUBSTITUTES INCLUDING A SUBSTITUTE MORPHOLIN, PREPARATION AND PHARMACEUTICAL APPLICATION THEREOF
JP2014528433A5 (cg-RX-API-DMAC7.html)
JP2019505541A5 (cg-RX-API-DMAC7.html)
US11319324B2 (en) Pyrazolo-pyrrolo-pyrimidine-dione derivatives as P2X3 inhibitors
CN102762208A (zh) 作为ck2抑制剂的吡唑嘧啶和相关杂环
CN107667092B (zh) 作为fgfr4抑制剂的甲酰化n-杂环衍生物
JP2017511365A5 (cg-RX-API-DMAC7.html)
US20160045505A1 (en) Compounds and compositions for the treatment of parasitic diseases
US20240158418A1 (en) EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS
HRP20241222T1 (hr) Makrociklički spojevi kao agonisti sting, te postupci i njihova upotreba
JP2020526549A5 (cg-RX-API-DMAC7.html)
NZ728122A (en) 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
WO2017157792A1 (en) Combinations of copanlisib
JP2014503590A5 (cg-RX-API-DMAC7.html)
JP2025528766A (ja) Her2を調節するための化合物および方法
CN113332292A (zh) 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物
US20210179557A1 (en) Substituted tetrahydrocyclopenta[c]pyrroles, substituted dihydropyrrolizines, analogues thereof, and methods using same